2016 American Transplant Congress
Positive Lymphocytes Flow Cytometry Crossmatch Due to AT1r Antibodies in Absence of HLA-DSA.
The angiotensin II type 1 receptor (AT1r) plays a key role in the renin-angiotensin system. Anti-AT1R antibodies (Abs) have been associated with both acute and…2015 American Transplant Congress
Protocol Donor Specific Antibody Monitoring After Kidney Transplantation: What Is the Utility?
De novo DSA has been shown to be a negative predictor of graft outcomes. However, the utility of routine DSA monitoring in the overall kidney…2015 American Transplant Congress
Number of Antigen Targets: A Key Parameter for Accurate Flow Cytometry Crossmatch Interpretation of Weak DSA
BACKGROUND: Flow cytometry crossmatch (FCXM) results are used to assess the safety of a transplant across pre-existing DSA. The number of targets on donor cells…2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?
Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high…2015 American Transplant Congress
“Unexpected” Positive Crossmatchs in Zero-HLA-A-B-DR Mismatched or HLA-DR-Matched Organs
Deceased donor kidney allocation is currently prioritized by HLA-A,-B and-DR serologic matching, which disregards both specificity at the allele level, and the contributions of HLA-C,-DQ,…
American Transplant Congress abstracts